Iradimed (IRMD) Non-Current Deffered Revenue (2013 - 2026)

Iradimed (IRMD) has 14 years of Non-Current Deffered Revenue data on file, last reported at $3.8 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $3.8 million, up 17.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (up 17.35% YoY), and the FY2025 annual result was $4.0 million, up 32.91% from the prior year.
• Non-Current Deffered Revenue slipped to $3.8 million in Q1 2026 per IRMD's latest filing, from $4.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.0 million in Q4 2025 and troughed at $1.4 million in Q4 2022.
• A 5-year average of $2.8 million and a median of $2.8 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue slipped 29.82% in 2022, then surged 103.14% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2022, then surged by 103.14% to $2.8 million in 2023, then increased by 7.14% to $3.0 million in 2024, then surged by 32.91% to $4.0 million in 2025, then slipped by 5.56% to $3.8 million in 2026.
• Business Quant data shows IRMD's Non-Current Deffered Revenue at $3.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.6 million in Q3 2025.